Drug class
CD123-directed antibody-drug conjugate (ADC); indolinobenzodiazepine DNA-alkylating antineoplastic
Mechanism of action
Pivekimab sunirine is a humanised anti-CD123 IgG1 antibody-drug conjugate. After binding to CD123-expressing cells and internalisation, intracellular processing releases the FGN849 indolinobenzodiazepine pseudodimer payload, which alkylates DNA, causes DNA strand breaks and induces apoptosis and cell death.
General use cases
- Treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), under the US product indication approved in May 2026.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
